Due to concerns about its safety, Delhi has restricted the use of the company’s coronavirus treatment
Due to concerns about its safety, India has announced that it will not add Merck’s Covid-19 pills to its national treatment plan. According to the country’s Medical Research Council, it causes fetal defects and cell changes.
On Wednesday, the state-run Indian Medical Research Council (ICMR) said it had realized “The main security issue.”
“It can cause teratogenic and mutagenicity, as well as cartilage damage and muscle damage,” ICMR Director General Balram Bhargava said. “More importantly, if you take this drug, you must contraceptive for three months, because the child born may have problems and have teratogenic effects.”
Teratogens are substances that can impair fetal development, and mutagenic drugs can alter the genetic makeup of subjects.
Merck claims that research on its drug proves that it does not cause birth defects or cancer, and that the research actually used higher doses and longer administration times than drugs commonly used in humans.
“WHO has not included it, and the UK has not yet included it. So far, the current recommendation is that it is not part of the national team’s remuneration,” Bhargava said.
The drug was approved by Indian regulators in December and was originally scheduled to be sold on the private market next week.
So far, neither Merck nor the lab of Dr. Reddy, an Indian drugmaker that plans to launch generic drugs, have responded to media requests for comment.
The drug has been approved for use in other parts of the world, including the United Kingdom, Japan, and Denmark.
Nevertheless, the test data is disappointing, and many countries choose to use Pfizer’s more effective Covid-19 pills.
You can share this story on social media: